SLC3A2 and central nervous system cancer: In conclusion, SLC3A2 might promote tumor proliferation, progression, metastasis, hemorrhage, and metabolic changes through mechanisms like disulfidptosis, ultimately lowering the overall survival rate of glioma patients.